No Data
Due to restricted share units received, Genor Biopharma-B (06998) issued 0.125 million shares.
Jahwa Biological-B (06998) announced that on October 28, 2024, the company selected participants for...
Rare Hong Kong shell listing, Jiahe Biology, which once had a market cap of tens of billions, has become a "shell".
A rare shell borrowing trade has emerged in the Hong Kong stock market. Recently, Wu Wei from "Investor's Network" reported that Jiahe Biotech (06998.HK) announced that it will acquire Yiteng Pharmacy through a merger. After the merger, the original shareholders of Yiteng Pharmacy will hold 77.43% of the shares of the merged company, while the original shareholders of Jiahe Biotech will hold 22.57% of the shares of the merged company. Ni Xin, the actual controller of Yiteng Pharmacy, will become the controlling shareholder of the new company. He is also the founder, chairman, and CEO of Yiteng Pharmacy. In the A-share market, this type of trade is generally known as a "shell acquisition listing", where smaller listed companies acquire shares of target companies by issuing shares. After the transaction is completed,
Jiawei Bio - B [06998] is now trading at HKD 2.02, with a rise of 10.99%.
As of 13:47, Bio-Joint Corporation B [06998] reported a price of 2.02 Hong Kong dollars, up 0.2 Hong Kong dollars or 10.99% from the closing price of 1.82 Hong Kong dollars yesterday. The trading volume was 0.7659 million Hong Kong dollars. The highest price today is 2.02 Hong Kong dollars, and the lowest price is 1.8 Hong Kong dollars. Calculated based on the closing price from yesterday, the 10-day average price is 1.81 Hong Kong dollars, and the 50-day average price is 1.47 Hong Kong dollars. The current price-earnings ratio is -1.24 times, and the 14-day strength index is 60.00.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
Yiteng Jia and Renhe "turn around", launching the first shot of "value leapfrogging" in the cold winter of biomedical capital.
With this integration, the new company will have a dual advantage in R&D and commercialization, making it more in line with the current market's valuation trend for Biopharma companies, thus having the potential for value reconstruction.
No Data
No Data